文献速递胸部肿瘤放疗放疗物理与技术

第三代EGFR-TKI联合胸部放疗的NSCLC患者放射性肺炎风险因素

Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy.
PubMed 文献 · Radiat Oncol · 2025-05-09

该回顾性研究纳入42例接受第三代EGFR-TKI联合胸部放疗的NSCLC患者,61.9%发生放射性肺炎(RP),33.3%发生≥2级RP。GTV≥39 ml和全肺V20≥14.95%是RP的独立危险因素,调整肺剂量学参数可降低RP风险。

要点

  • 第三代EGFR-TKI联合胸部放疗的NSCLC患者RP发生率高达61.9%。
  • GTV≥39 ml和全肺V20≥14.95%是RP独立危险因素。
  • ≥2级RP均发生在放疗后6个月内,中位时间3.69个月。

核心结论

  • 第三代TKI联合胸部放疗显著增加RP发生率,调整肺剂量学参数可降低风险。
  • 对于原发肿瘤进展的NSCLC患者,加用胸部放疗的时机和剂量须严格控制。

研究设计与样本

  • 回顾性研究,纳入2023年1月至2024年9月宁夏医科大学总医院接受第三代EGFR-TKI联合胸部放疗的NSCLC患者42例。
  • RP依据CT扫描临床症状诊断,按CTCAE 5.0分级,采用单因素和多因素logistic回归分析危险因素。

主要发现

  • 42例患者中26例(61.9%)发生RP,14例(33.3%)发生≥2级RP。
  • ≥2级RP均发生在接受胸部放疗后6个月内,从放疗到RP的中位时间为3.69个月(范围2-10个月)。
  • GTV≥39 ml和全肺V20≥14.95%是RP发生的独立危险因素。

关键数值与推荐

  • GTV≥39 ml为RP独立危险因素。
  • 全肺V20≥14.95%为RP独立危险因素。

临床怎么用

  • 对接受第三代EGFR-TKI联合胸部放疗的NSCLC患者,应关注GTV和全肺V20等剂量学参数以降低RP风险。
  • 在原发肿瘤进展的患者中,加用胸部放疗的时机和剂量需严格把控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-small cell lung cancer (NSCLC) patients receiving third-generation EGFR TKIs with thoracic radiotherapy (TRT) significantly prolong survival and also increase the incidence of radiation pneumonitis (RP). The aim of our study was to investigate the incidence and risk factors of RP in NSCLC patients receiving third-generation EGFR TKIs and TRT. PATIENTS AND METHODS: We retrospectively evaluated NSCLC patients who received both third-generation EGFR TKIs and TRT at the General Hospital of Ningxia Medical University from January 2023 to September 2024. RP was diagnosed by clinical symptoms on computed tomography (CT) scans and graded according to the Common Terminology Criteria for Adverse Events 5.0. Risk factors for RP were determined by univariate and multivariate logistic regression analysis. RESULTS: Of the 42 patients included, 26 (61.9%) developed RP and 14 (33.3%) developed grade ≥ 2 RP. Grade ≥ 2 RP all occurred within 6 months of receiving TRT, and the median time from TRT to RP was 3.69 months (2-10 months). GTV ≥ 39 ml and total lung V20 ≥ 14.95% were found to be independent risk factors for RP development. CONCLUSION: The strategy of combining a third-generation TKI with TRT significantly increases the incidence of RP, and the risk of RP in these patients can be reduced by adjusting lung radiation dosimetry parameters. In NSCLC patients taking triple-generation TKIs with primary tumour progression, the timing and dose of TRT addition must be strictly controlled to optimise the therapeutic strategy and reduce the incidence of RP. CLINICAL TRIAL NUMBER: Not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao N, Xiong L, Bai X, et al. Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy. Radiat Oncol. 2025. PMID: 40346592. doi:10.1186/s13014-025-02649-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。